Gupta M, et al. - Whether 0.2 mg/kg nalbuphine intravenous (IV) pretreatment would be an effective preventive strategy against the development of etomidate induced myoclonus (EM), was investigated among 100 patients undergoing elective surgeries under general anesthesia and were randomly allocated to one of two groups to receive: 10 ml of normal saline (Group I) or 0.2 mg/kg nalbuphine in 10 ml of normal saline (Group II) 150 s before injection etomidate 0.3 mg/kg administered IV over 20 s. Findings revealed that the incidence and severity of EM was significantly reduced with nalbuphine 0.2 mg/kg IV pretreatment, with side-effect profile comparable to saline placebo.